Dec 6 (Reuters) - MediciNova Inc :

* MEDICINOVA ANNOUNCES ADDITIONAL POSITIVE RESULTS REGARDING THE EFFECTS OF MN-001 (TIPELUKAST) ON SERUM LIPID PANEL IN TYPE 2 DIABETES AND NAFLD PATIENTS PRESENTED AT IDF 2022 CONGRESS, THE ANNUAL MEETING OF THE INTERNATIONAL DIABETES FEDERATION

* MEDICINOVA - MN-001 SIGNIFICANTLY REDUCED SERUM TRIGLYCERIDES IN PARTICIPANTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA

* MEDICINOVA INC - COMPARED TO SUBJECTS WITHOUT T2DM, T2DM GROUP SHOWED A GREATER REDUCTION IN SERUM TRIGLYCERIDE LEVELS AT WEEK 8

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))